Radient Pharmaceuticals Corporation fka RXPC

[ED20332]

The Rosen Law Firm Announces Investigation of Securities Claims Against Radient Pharmaceuticals Corporation – RPC


Press Release Source: The Rosen Law Firm, P.A. On Monday March 7, 2011, 9:00 pm EST


NEW YORK--(BUSINESS WIRE)-- The Rosen Law Firm, P.A. announces that it is investigating potential securities fraud claims against Radient Pharmaceuticals Corporation (AMEX:RPC - News) resulting from allegations that the Company may have issued materially inaccurate statements about the involvement of the prestigious Mayo Clinic in one of the Company’s clinical trials.



On January 18, 2011, Radient issued a press release announcing “progress on its clinical study with the Mayo Clinic…” In connection with the clinical study the Company claimed that samples were being tested by the Company and the Mayo Clinic to directly compare the efficacy of the Onko-Sure test with another test.



On March 7, 2011, TheStreet.com issued an article refuting claims that the Mayo Clinic was conducting a clinical trial with Radient. In the article, a Mayo Clinic spokesperson is quoted as stating that: “Mayo is not engaged in clinical studies with Radient and does not have a partnership agreement with Radient.” The Mayo Clinic spokesperson added that: “The services Mayo was required to provide to Radient have been fulfilled. Any clinical study results about Onko-Sure would be provided by Radient, not Mayo Clinic.” As a result of this adverse news, the price of Radient stock on March 7, 2011 fell, damaging investors.



The Rosen Law Firm is investigating a securities class action lawsuit on behalf of Radient investors. If you purchased Radient stock between January 18, 2011 and March 7, 2011, please visit the website at http://www.rosenlegal.com for more information. You may also contact Laurence Rosen, Esq., or Phillip Kim, Esq. of The Rosen Law Firm toll free at 866-767-3653 or via e-mail at [e-mail] or [e-mail].



The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.